Arie Belldegrun, M.D.


Arie Belldegrun

Arie Belldegrun, MD, is the Chairman of Bellco Capital, and the Executive Chairman and Co-Founder of Allogene Therapeutics, a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. A visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone (Zytiga), developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and as co-Chairman of Breakthrough Properties LLC. He serves as director of IconOVir Bio, Inc and is also co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston and Los Angeles. Arie is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and is a Fellow of the American Association of Genitourinary Surgeons.

Rebecka Belldegrun, M.D.

President & Chief Executive Officer

Bell Co Capital11 18 N Gingold EDIT 206

Rebecka Belldegrun, M.D., is the President and Chief Executive Officer of Bellco Capital. Rebecka currently serves on the Boards of Breakthrough Properties, First Media Corporation and Baby First TV, and as a Trustee at the Los Angeles County Museum of Art (LACMA). Additionally, she serves on the Board of Trustees at Caltech University and the Interdisciplinary Center in Israel. Previously, Rebecka served as Chairman of the Board of Trustees at the Brentwood School in Los Angeles, The University of Pennsylvania Parents Leadership Committee, as member of the Board of Advisors to the RAND Corporation, and the USC Center on Public Diplomacy.

Rebecka graduated from the Sackler School of Medicine at Tel Aviv University, and completed her residency in Ophthalmology and a postdoctoral Fellowship in Corneal Surgery at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Prior to founding Bellco Capital, Rebecka established Intertech Corporation, a New York and Los Angeles-based Real Estate company specializing in development, investments, and acquisitions. During her role as President of Intertech, she built a portfolio of hotels and commercial properties in Europe, Scandinavia, and Israel.

Josh Bradley

Chief Investment Officer

Bell Co Capital11 18 N Gingold EDIT 057

Josh Bradley is the Chief Investment Officer at Bellco Capital. Josh oversees Bellco’s investment strategy and works closely with its portfolio companies and strategic partners. Josh also serves on the board of directors of several privately held companies, including Breakthrough Properties, ByHeart and First Media. Prior to joining Bellco Capital, Josh practiced law at Sullivan & Cromwell in New York, London and Sydney. During his time in private practice, Josh advised private equity firms, banks, corporations and governmental organizations on strategic transactions, including mergers and acquisitions, initial public offerings, financial restructurings and joint ventures, with an aggregate value of more than $250 billion. Prior to his time in private practice, Josh clerked for the Honorable Robert R. Beezer on the Court of Appeals for the Ninth Circuit.

Josh received his B.A. with distinction from the University of Virginia and his J.D. from the University of Virginia’s School of Law, where he served as Articles Editor of the Virginia Law Review and was elected to the Order of the Coif.